Skip to main content
padlock icon - secure page this page is secure

Silver-Coated Nanoparticles Combined with Doxorubicin for Enhanced Anticancer Therapy

Buy Article:

$106.73 + tax (Refund Policy)

Combination therapy with different functional drugs has been proved to be an effective strategy for cancer treatments by achieving cooperative therapeutic efficacy and reducing drug side effects. In this study, a novel combination anticancer system was designed by coating silver nanoparticles in the poly(aspartic acid) (PAsp) shell of polymer micelle via the in situ reduction of silver ions and encapsulating doxorubicin (DOX) into the micellar poly(ε-caprolactone) (PCL) core through hydrophobic interaction. This combination system not only avoided aggregation of the silver nanoparticles but also improved the bioavailability of DOX. As a result, it exhibited enhanced antitumor activity against HepG2 tumor cells compared with single silver-coated or DOX-loaded nanoparticles because of the combined anticancer effects of nanosilver and DOX. Therefore, this combination therapeutic system could be a potential candidate for enhanced anticancer therapy.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: ANTICANCER; COMBINATION THERAPY; DOXORUBICIN; NANOPARTICLE; SILVER

Document Type: Research Article

Publication date: February 1, 2018

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more